Synthesis 2012(8): 1152-1154  
DOI: 10.1055/s-0031-1289711
PSP
© Georg Thieme Verlag Stuttgart ˙ New York

An Efficient and Safe Method for the Multigram Synthesis of trans-2-(Trifluoromethyl)cyclopropylamine

Vladimir S. Yarmolchuka,b, Andrii V. Bezdudnya, Nataliya A. Tolmachevaa, Oleg Lukin*c, Alexander N. Boykoc, Alexey Chekotyloc, Andrei A. Tolmacheva,c, Pavel K. Mykhailiuk*a,b
a Enamine Ltd., Alexander Matrosov St. 23, Kiev 01103, Ukraine
e-Mail: pavel.mykhailiuk@gmail.com;
b Department of Chemistry, Kiev National Taras Shevchenko University, Volodymyrska St. 64, Kiev 01033, Ukraine
c ChemBioCenter, Kiev National Taras Shevchenko University, Volodymyrska St. 62, Kiev 01033, Ukraine
Fax: +38(44)2351273; e-Mail: oleg.lukin@univ.kiev.ua;
Weitere Informationen

Publikationsverlauf

Received 28 November 2011
Publikationsdatum:
15. Februar 2012 (eFirst)

Abstract

trans-2-(Trifluoromethyl)cyclopropylamine was prepared on a multigram scale from readily accessible 4,4,4-trifluorobut-2-enoic acid in five steps. The key step was a high-yielding cyclopropane ring formation from 4,4,4-trifluorobut-2-enoic acid methoxymethyl amide under Corey-Chaykovsky reaction conditions.

    References

  • 1 Bezdudny AV. Klukovsky D. Simurova N. Mykhailiuk PK. Shishkin OV. Pustovit YM. Synthesis  2011,  119 
  • For reviews, see:
  • 2a Brackmann F. de Meijere A. Chem. Rev.  2007,  107:  4493 
  • 2b Reichelt A. Martin SF. Acc. Chem. Res.  2006,  39:  433 
  • 2c Salaün J. Top. Curr. Chem.  2000,  207:  1 
  • 3 Of the approximately 1350 small-molecule FDA-approved drugs, 43 contain the trifluoromethyl group and 23 contain the cyclopropyl group. See: Wishart DS. Knox C. Guo AC. Cheng D. Shrivastaya S. Tzur D. Gautam B. Hassanali M. Nucleic Acids Res.  2008,  36:  D901 
  • For recent reviews and relevant reports, see:
  • 4a Mikami K. Fustero S. Sánchez-Roselló M. Aceña JL. Soloshonok VA. Sorochinsky AE. Synthesis  2011,  3045 
  • 4b Sorochinsky AE. Soloshonok VA. J. Fluorine Chem.  2010,  131:  127 
  • 4c O’Hagan D. J. Fluorine Chem.  2010,  131:  1071 
  • 4d Artamonov OS. Mykhailiuk PK. Voievoda NM. Volochnyuk DM. Komarov IV. Synthesis  2010,  443 
  • 4e Purser S. Moore PR. Swallow S. Gouverneur V. Chem. Soc. Rev.  2008,  37:  320 
  • 4f Hagmann WK. J. Med. Chem.  2008,  51:  4360 
  • 4g Müller K. Faeh C. Diederich F. Science  2007,  317:  1881 
  • 4h Kirsch P. Modern Fluoroorganic Chemistry   Wiley-VCH; Weinheim: 2004. 
  • 6a McBee ET. Pierce OR. Smith DD. J. Am. Chem. Soc.  1954,  76:  3722 
  • 6b Bevilacqua PF. Keith DD. Roberts JL. J. Org. Chem.  1984,  49:  1430 
  • 7 Gladwell IR, Matthews JG, and Pettmann AJ. inventors; Patent  WO2005/023773 (A1) US2005/0096354 (A1). The preparation of compound 3 from 2 was described, but no characterization data for 3 were given: (Pfizer Ltd; Pfizer Inc.) 2005
  • 8 Morandi B. Cheang J. Carreira E. M. Org. Lett.  2011,  13:  3080 
5

For the list of occupational exposure limits for SF4, see the Advisory reports from the Health Council of The Netherlands at http://www.gezondheidsraad.nl/en/publications.